Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 8/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | HCAR1 | Q9BXC0 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28460135 | 0.82 | KCNN4 (0.52) | KCNN4P2RX7SCN9AHCAR1ALDH1A1 | |
| SCHEMBL8653700 | 0.80 | KCNN4 (0.60) | KCNN4P2RX7ALDH1A1 | |
| SCHEMBL8758973 | 0.76 | KCNN4 (0.49) | KCNN4P2RX7SCN9AHCAR1ALDH1A1 | |
| SCHEMBL28188336 | 0.76 | KCNN4 (0.47) | KCNN4P2RX7SCN9AHCAR1ALDH1A1 | |
| SCHEMBL10711024 | 0.76 | MAPK1 (0.56) | KCNN4P2RX7ALDH1A1 | |
| Potassium SCHEMBL9513366 | 0.75 | KCNN4 (0.48) | KCNN4P2RX7SCN9AHCAR1ALDH1A1 | |
| SCHEMBL9513354 | 0.75 | KCNN4 (0.48) | KCNN4P2RX7SCN9AHCAR1ALDH1A1 | |
| SCHEMBL14112954 | 0.74 | KCNN4 (0.54) | KCNN4 | |
| SCHEMBL8679056 | 0.74 | MAPK1 (0.43) | KCNN4ALDH1A1 | |
| SCHEMBL9769964 | 0.72 | KCNN4 (0.54) | KCNN4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
| EP-2288603-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009150614-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | KCNN4 869/4885P2RX7 150/4885SCN9A 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.